New drug cocktail aims to wipe out breast cancer before surgery
NCT ID NCT07396324
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study is testing whether adding an immunotherapy drug called QL1706 to standard chemotherapy before surgery can improve outcomes for people with HR-positive, HER2-negative breast cancer. About 55 participants will receive the combination, and researchers will measure how many have no cancer cells left at the time of surgery. The trial is currently recruiting.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Iparomlimab and Tuvonralimab (QL1706) plus chemotherapy (paclitaxel and carboplatin)
What this could lead to
If successful, this could lead to a more effective pre-surgery treatment for HR+/HER2- breast cancer, potentially increasing the chance of no cancer remaining at surgery.
What could go wrong
This is an early Phase 2 trial with only 55 participants and no control group, so results may not be conclusive. The combination may cause significant side effects from chemotherapy and immunotherapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HR-POSITIVE/HER2-NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••